ARS Pharmaceuticals Inc (SPRY): Next-Year EPS Estimate 45.37%
As of 2026-06-11, ARS Pharmaceuticals Inc (SPRY) has a next-year EPS growth estimate of 45.37%.
On 2026-05-28, analyst consensus for SPRY's next-year EPS growth shifted from 45.60% to 45.37% — a negative change of 0.23 percentage points. The revised estimate has been sustained across 11 subsequent trading sessions. Current-year growth is projected at -0.57%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 45.37%
- EPS growth this year
- -0.57%
- EPS next quarter (est)
- -$0.48
- Last price
- $9.59
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-11 | 45.37% | -0.57% | -$0.48 | $9.59 |
| 2026-06-10 | 45.37% | -0.57% | -$0.48 | $9.26 |
| 2026-06-09 | 45.37% | -0.57% | -$0.48 | $9.41 |
| 2026-06-08 | 45.37% | -0.57% | -$0.48 | $8.99 |
| 2026-06-07 | 45.37% | -0.57% | -$0.48 | $8.56 |
| 2026-06-04 | 45.37% | -0.57% | -$0.48 | $9.07 |
| 2026-06-03 | 45.37% | -0.57% | -$0.48 | $8.75 |
| 2026-06-02 | 45.37% | -0.57% | -$0.48 | $8.90 |
| 2026-06-01 | 45.37% | -0.57% | -$0.48 | $9.43 |
| 2026-05-31 | 45.37% | -0.57% | -$0.48 | $9.07 |
| 2026-05-28 | 45.37% | -0.57% | -$0.48 | $9.40 |
| 2026-05-27 | 45.60% | -0.57% | -$0.48 | $8.50 |
| 2026-05-26 | 45.60% | -0.57% | -$0.48 | $8.17 |
| 2026-05-25 | 45.60% | -0.57% | -$0.48 | $7.94 |
| 2026-05-24 | 45.60% | -0.57% | -$0.48 | $7.94 |
| 2026-05-21 | 45.60% | -0.57% | -$0.48 | $8.23 |
| 2026-05-20 | 45.60% | -0.57% | -$0.48 | $7.80 |
| 2026-05-19 | 45.60% | -0.57% | -$0.48 | $7.17 |
| 2026-05-18 | 45.60% | -0.57% | -$0.48 | $7.30 |
| 2026-05-17 | 47.15% | 1.26% | -$0.47 | $7.43 |
| 2026-05-14 | 52.03% | 9.20% | -$0.52 | $7.94 |
| 2026-05-13 | 52.03% | 9.20% | -$0.52 | $8.31 |
| 2026-05-12 | 52.03% | 9.20% | -$0.52 | $8.63 |
| 2026-05-11 | 52.03% | 9.20% | -$0.52 | $8.60 |
| 2026-05-10 | 52.03% | 9.20% | -$0.52 | $8.74 |
| 2026-05-07 | 58.10% | 12.81% | -$0.49 | $9.00 |
| 2026-05-06 | 58.10% | 12.81% | -$0.49 | $9.28 |
| 2026-05-05 | 58.10% | 12.81% | -$0.49 | $9.03 |
| 2026-05-04 | 58.10% | 12.81% | -$0.49 | $8.83 |
| 2026-05-03 | 58.10% | 12.81% | -$0.49 | $8.56 |
Screen Performance
Aggregate stats across all 1781 tickers our top-EPS-revision screen has flagged over the past 71 days.
- Median return since detection
- +3.8%
- % of tickers in the green
- 58%
- Median return on winners
- +18.5%
- Large revisions captured
- 788
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is ARS Pharmaceuticals Inc's next-year EPS growth estimate?▾
As of 2026-06-11, ARS Pharmaceuticals Inc (SPRY) has a next-year EPS growth estimate of 45.37%, based on analyst consensus.
When was the latest EPS estimate revision for SPRY?▾
The most recent revision occurred on 2026-05-28, when analysts adjusted the next-year EPS growth estimate from 45.60% to 45.37%.
What sector and industry does ARS Pharmaceuticals Inc belong to?▾
ARS Pharmaceuticals Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. SPRY appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. ARS Pharmaceuticals Inc (SPRY) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports